Clinical Trials Browser

Completed × OTHER × obinutuzumab × Clear all

NCT04703686 2026-03-16

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Phase 2 Completed

Lymphoma, Mantle-Cell

NCT02896582 2026-01-14

LyMa101

Phase 2 Completed

Lymphoma, Mantle-Cell

NCT02666898 2025-11-26

ICLL07GAI

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual

NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Phase 1/2 Completed

32 enrolled 9 charts

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02558816 2025-07-24

OAsIs

Phase 1/2 Completed

Lymphoma, Mantle-Cell

NCT01995669 2025-06-24

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Phase 1/2 Completed

66 enrolled 13 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02750670 2025-06-22

Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05169658 2025-04-11

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT02950051 2024-12-30

GAIA

Phase 3 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT02529852 2024-09-19

A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Phase 1/2 Completed

59 enrolled 11 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02962401 2023-08-29

RemodelWM3

Phase 2 Completed

Waldenstrom Macroglobulinemia

NCT03010358 2023-08-08

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Phase 1/2 Completed

24 enrolled 16 charts

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Prolymphocytic, B-Cell

NCT02758665 2023-01-17

CLL2-GiVe

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03276468 2023-01-10

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Phase 2 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT02877550 2022-06-10

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT02736617 2022-01-05

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Phase 2 Completed

10 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT03755947 2021-02-02

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

LymphoidOther hematologic neoplasm

Disease, Leukemia, Lymphocytic, Chronic, B-Cell